|11.06||-0.2300||-2.04%||Vol 14.41K||1Y Perf 61.43%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||15.00||Analyst Rating||Strong Buy 1.00|
|Potential %||35.62||Finscreener Ranking||★★★★+ 56.86|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★ 48.00|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★+ 49.69|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||148.09M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||54.06||Earnings Date||11th Mar 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2020||0.01||-0.17||-1 800.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.01|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||16.98K|
|Avg. Monthly Volume||30.37K|
|Avg. Quarterly Volume||32.75K|
Champions Oncology Inc. (NASDAQ: CSBR) stock closed at 11.06 per share at the end of the most recent trading day (a -2.04% change compared to the prior day closing price) with a volume of 14.41K shares and market capitalization of 148.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 143 people. Champions Oncology Inc. CEO is Ronnie Morris.
The one-year performance of Champions Oncology Inc. stock is 61.43%, while year-to-date (YTD) performance is 2.5%. CSBR stock has a five-year performance of 203.01%. Its 52-week range is between 6.8 and 14.68, which gives CSBR stock a 52-week price range ratio of 54.06%
Champions Oncology Inc. currently has a PE ratio of -94.90, a price-to-book (PB) ratio of 19.37, a price-to-sale (PS) ratio of 3.87, a price to cashflow ratio of 51.40, a PEG ratio of 2.32, a ROA of -5.90%, a ROC of -11.48% and a ROE of -21.71%. The company’s profit margin is -3.52%, its EBITDA margin is 0.90%, and its revenue ttm is $39.22 Million , which makes it $2.93 revenue per share.
Of the last four earnings reports from Champions Oncology Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Champions Oncology Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Champions Oncology Inc. is Strong Buy (1), with a target price of $15, which is +35.62% compared to the current price. The earnings rating for Champions Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Champions Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Champions Oncology Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.48, ATR14 : 0.64, CCI20 : -79.52, Chaikin Money Flow : -0.13, MACD : -0.04, Money Flow Index : 38.51, ROC : -3.83, RSI : 46.33, STOCH (14,3) : 32.47, STOCH RSI : 0.35, UO : 48.09, Williams %R : -67.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Champions Oncology Inc. in the last 12-months were: Abba David Poliakoff (Sold 0 shares of value $-32 100 ), David Sidransky (Sold 0 shares of value $-91 002 ), Philip Breitfeld (Sold 0 shares of value $-15 210 ), Philip Breitfeld (Sold 31 443 shares of value $356 976 ), Scott R. Tobin (Option Excercise at a value of $109 200)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.